

Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation

Children's Hospital & Research Center Oakland, Oakland, California, United States

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

Universitätsklinikum Hamburg, Hamburg, , Germany

University Medical Center Mainz, Center of Pediatric and Adolescent Medicine Villa Metabolica, Mainz, , Germany

NIHR/Wellcome Trust Birmingham CRF, Queen Elizabeth Hospital, Birmingham, , United Kingdom

Central Manchester University Hospitals NHS Foundation Trust, Manchester, , United Kingdom

Salford Royal NHS Foundation Trust, Salford, , United Kingdom

The primary objective of this study is to evaluate the effect of 2.0 mg/kg/week BMN 110 in a patient population that has limited ambulation, in a period of up to 144 weeks.